Related Experiment Videos
Drug solubilization in lung surfactant.
T S Wiedmann1, R Bhatia, L W Wattenberg
1Department of Pharmaceutics, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA. weidm001@tc.umn.edu
Summary
Glucocorticosteroids show enhanced solubility in lung surfactant, aiding the search for lung cancer chemopreventive drugs. This interaction is crucial for developing targeted therapies with improved safety profiles.
Area of Science:
- Pharmacology
- Biochemistry
- Oncology
Background:
- Lung cancer chemoprevention requires agents with high therapeutic indices.
- Glucocorticosteroids are potential candidates, but their interaction with lung surfactant is not well understood.
Purpose of the Study:
- To determine the relative affinity of glucocorticosteroids for lung surfactant.
- To identify potential chemopreventive agents for lung cancer with improved therapeutic indices.
Main Methods:
- Determined aqueous solubility and solubilization in bovine lung extract (Survanta) for four glucocorticosteroids (budesonide, triamcinolone acetonide, dexamethasone, flunisolide) using dialysis.
- Measured solubility as a function of temperature.
Main Results:
- Aqueous solubilities at 37°C varied among the steroids.
- Survanta significantly enhanced drug solubility, with specific solubilization ratios observed.
- Solubilization generally increased with temperature, though surfactant lipid phase transitions caused complexity.
Conclusions:
- Lung surfactant enhances the solubilization of glucocorticosteroids.
- This enhanced interaction is relevant to type II lung cells, which secrete surfactant and are susceptible to cancer.
- Findings support the development of glucocorticosteroids as lung cancer chemopreventive agents.